SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract

American Journal of Surgical Pathology

Volumn 38, Issue 9, 2014, Pages 1282-1289

  Bishop, Justin A ^a,b   Antonescu, Cristina R ^d   Westra, William H ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Otolaryngology/Head and Neck Surgery ^*  (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

INI 1; rhabdoid; sinonasal tract; sinonasal undifferentiated carcinoma; SMARCB1; SNF5

Indexed keywords

DNA BINDING PROTEIN; NONHISTONE PROTEIN; SMARCB1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOPSY; CARCINOMA; CELL NUCLEUS; CHEMISTRY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MIDDLE AGED; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANASAL SINUS; PARANASAL SINUS TUMOR; PATHOLOGY; TIME; TISSUE MICROARRAY; TREATMENT OUTCOME;

ADULT; AGED; BIOPSY; CARCINOMA; CELL NUCLEUS; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; FEMALE; GENE DELETION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARANASAL SINUS NEOPLASMS; PARANASAL SINUSES; TIME FACTORS; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84906794603     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000285     Document Type: Article

References (44)

1. Batsakis JG, Rice DH, Solomon AR. The pathology of head and neck tumors: squamous and mucous-gland carcinomas of the nasal cavity, paranasal sinuses, and larynx, part 6. Head Neck Surg. 1980; 2:497-508.
2. Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck. 2012;34:877-885.
3. Ayiomamitis A, Parker L, Havas T. The epidemiology of malignant neoplasms of the nasal cavities, the paranasal sinuses and the middle ear in Canada. Arch Otorhinolaryngol. 1988;244:367-371.
4. Hayes RB, Kardaun JW, de Bruyn A. Tobacco use and sinonasal cancer: a case-control study. Br J Cancer. 1987;56: 843-846.
5. Mannetje A, Kogevinas M, Luce D, et al. Sinonasal cancer, occupation, and tobacco smoking in European women and men. Am J Ind Med. 1999;36:101-107.
6. Jackson RT, Fitz-Hugh GS, Constable WC. Malignant neoplasms of the nasal cavities and paranasal sinuses: (a retrospective study). Laryngoscope. 1977;87:726-736.
7. Bishop JA, Guo TW, Smith DF, et al. Human papillomavirusrelated carcinomas of the sinonasal tract. Am J Surg Pathol. 2013; 37:185-192.
8. Alos L, Moyano S, Nadal A, et al. Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome. Cancer. 2009;115:2701-2709.
9. Larque AB, Hakim S, Ordi J, et al. High-risk human papillomavirus is transcriptionally active in a subset of sinonasal squamous cell carcinomas. Mod Pathol. 2014;27:343-351.
10. El-Mofty SK, Lu DW. Prevalence of high-risk human papillomavirus DNA in nonkeratinizing (cylindrical cell) carcinoma of the sinonasal tract: a distinct clinicopathologic and molecular disease entity. Am J Surg Pathol. 2005;29:1367-1372.
11. Bishop JA, Westra WH. NUT midline carcinomas of the sinonasal tract. Am J Surg Pathol. 2012;36:1216-1221.
12. French CA. NUT midline carcinoma. Cancer Genet Cytogenet. 2010;203:16-20.
13. Stelow EB, Bellizzi AM, Taneja K, et al. NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract. Am J Surg Pathol. 2008;32:828-834.
14. Hollmann TJ, Hornick JL. INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol. 2011;35:e47-e63.
15. Imbalzano AN, Jones SN. Snf5 tumor suppressor couples chromatin remodeling, checkpoint control, and chromosomal stability. Cancer Cell. 2005;7:294-295.
16. Judkins AR. Immunohistochemistry of INI1 expression: a new tool for old challenges in CNS and soft tissue pathology. Adv Anat Pathol. 2007;14:335-339.
17. Hoot AC, Russo P, Judkins AR, et al. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol. 2004;28:1485-1491.
18. Judkins AR, Mauger J, Ht A, et al. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol. 2004;28:644-650.
19. Biegel JA, Kalpana G, Knudsen ES, et al. The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res. 2002;62:323-328.
20. Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999;59:74-79.
21. Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg. 1996;85:56-65.
22. Biegel JA, Burk CD, Parmiter AH, et al. Molecular analysis of a partial deletion of 22q in a central nervous system rhabdoid tumor. Genes Chromosomes Cancer. 1992;5:104-108.
23. Biegel JA, Rorke LB, Emanuel BS. Monosomy 22 in rhabdoid or atypical teratoid tumors of the brain. N Engl J Med. 1989; 321:906.
24. Shashi V, Lovell MA, von Kap-herr C, et al. Malignant rhabdoid tumor of the kidney: involvement of chromosome 22. Genes Chromosomes Cancer. 1994;10:49-54.
25. Schofield DE, Beckwith JB, Sklar J. Loss of heterozygosity at chromosome regions 22q11-12 and 11p15.5 in renal rhabdoid tumors. Genes Chromosomes Cancer. 1996;15:10-17.
26. Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol. 2009;33:542-550.
27. Modena P, Lualdi E, Facchinetti F, et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res. 2005;65:4012-4019.
28. Le Loarer F, Zhang L, Fletcher CD, et al. Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material. Genes Chromosomes Cancer. 2014;53:475-486.
29. Cheng JX, Tretiakova M, Gong C, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol. 2008;21: 647-652.
30. Gleason BC, Fletcher CD. Myoepithelial carcinoma of soft tissue in children: an aggressive neoplasm analyzed in a series of 29 cases. Am J Surg Pathol. 2007;31:1813-1824.
31. Kohashi K, Oda Y, Yamamoto H, et al. SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: a special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma. Am J Surg Pathol. 2008;32:1168-1174.
32. Prophet EB, Mills B, Arrington JB, et al. AFIP Laboratory Methods in Histotechnology. Washington, DC: American Registry of Pathology; 1992.
33. Agaimy A, Rau TT, Hartmann A, et al. SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review. Am J Surg Pathol. 2014;38:910-920.
34. Perry A, Fuller CE, Judkins AR, et al. INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. Mod Pathol. 2005;18:951-958.
35. Wick MR, Ritter JH, Dehner LP. Malignant rhabdoid tumors: a clinicopathologic review and conceptual discussion. Semin Diagn Pathol. 1995;12:233-248.
36. Ogino S, Ro TY, Redline RW. Malignant rhabdoid tumor: A phenotype? An entity? A controversy revisited. Adv Anat Pathol. 2000;7:181-190.
37. Ginn KF, Gajjar A. Atypical teratoid rhabdoid tumor: current therapy and future directions. Front Oncol. 2012;2:114, 1-13.
38. Venkataraman S, Alimova I, Tello T, et al. Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells. J Neurooncol. 2012;107:517-526.
39. Lee S, Cimica V, Ramachandra N, et al. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival. Cancer Res. 2011;71:3225-3235.
40. D'Cunja J, Shalaby T, Rivera P, et al. Antisense treatment of IGFIR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells. Eur J Cancer. 2007;43:1581-1589.
41. Smith ME, Cimica V, Chinni S, et al. Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1. Proc Natl Acad Sci USA. 2011;108:319-324.
42. Alarcon-Vargas D, Zhang Z, Agarwal B, et al. Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors. Oncogene. 2006;25:722-734.
43. Smith ME, Cimica V, Chinni S, et al. Rhabdoid tumor growth is inhibited by flavopiridol. Clin Cancer Res. 2008;14:523-532.
44. Cimica V, Smith ME, Zhang Z, et al. Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen. BMC cancer. 2010;10:634.